Abstract: Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist, wherein the claimed invention provides a unit dose of an aqueous pharmaceutical solution, or aqueous pharmaceutical composition, housed in a device configured for intranasal administration to a patient, wherein the aqueous pharmaceutical solution consists of, or the aqueous pharmaceutical composition consists essentially of: (i) naloxone hydrochloride in an amount of about 9% by weight based on the total weight of the aqueous pharmaceutical solution; (ii) glycerin in an amount of about 1.4% by weight based on the total weight of the aqueous pharmaceutical solution; (iii) a citrate buffer system adjusted by hydrochloric acid and/or sodium hydroxide; and (iv) United States Pharmacopeia (USP)-grade Purified Water; wherein the pH of the aqueous pharmaceutical solution is from about 3.5 to about 4.

Abstract: The present invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer including a combination of (a) hydrogen peroxide and (b) hyaluronic acid or a salt thereof, wherein the hydrogen peroxide content in a final formulation is 0.1 to 3.5 weight percent.

Abstract: Described herein are wound dressings and methods of their use, wherein the wound dressings comprise a polymeric component. The polymeric component is a polyethyleneimine intermediate selected from the group consisting of: at least one R60 is —(CH2)3OH but less than 50% of all R60 are —(CH2)3OH; and the polyethyleneimine intermediate has a ratio of total quaternary amines to total hydroxyl groups of at least 1:1.

Abstract: The present disclosure relates to the field of antimicrobial compositions. More particularly, it concerns the use of a composition as an antimicrobial agent, the composition comprising ingredients selected from the group consisting of: (i) nona-2,6-dien-1-ol in combination with at least one ingredient selected from the group consisting of 3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and 2-isopropyl-5-methylphenol; (ii) gamma-dodecalactone in combination with at least one ingredient selected from the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii) (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv) cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v) 1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein the ingredients are present in an amount sufficient to provide an antimicrobial effect.

Abstract: A solution of uridine in saline, and optionally also containing beta-hydroxybutyrate, can be administered subcutaneously. A reservoir capable of holding a uridine solution in saline is described, the reservoir being fluidically linked to one or more infusion needles, and a pump configured to move the solution from the reservoir through the one or more infusion needles into a subject.

Abstract: This invention relates generally to a method of treating a crop with an agricultural product, where the method includes the steps of incorporating a cellulose nanocrystal-based emulsion into an agrochemical to produce the agricultural product and applying said agricultural product to said crop. The cellulose nanocrystal-based emulsion includes a continuous aqueous phase and a dispersed oil phase, where the continuous aqueous phase includes between about 0.25% and about 3% (w/w) of sulfonated cellulose nanocrystals, between about 0.25% and about 1% (w/w) of co-stabilizing biopolymer, and up to about 3.0% (w/w) of cationic crosslinker. The dispersed oil phase includes a plant-based oil.

Abstract: Provided herein are methods of using drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist, wherein the claimed invention provides a method of treating an opioid overdose or symptom thereof in a patient in need thereof, comprising intranasally administering to the patient an aqueous pharmaceutical solution consisting of, or an aqueous pharmaceutical composition consisting essentially of: (i) naloxone hydrochloride in an amount of about 9% by weight based on the total weight of the aqueous pharmaceutical solution; (ii) glycerin in an amount of about 1.4% by weight based on the total weight of the aqueous pharmaceutical solution; (iii) a citrate buffer system adjusted by hydrochloric acid and/or sodium hydroxide; and (iv) United States Pharmacopeia (USP)—grade Purified Water; wherein the pH of the aqueous pharmaceutical solution is from about 3.5 to about 4.

Abstract: Disclosed herein is a method for producing a nanoframe of Prussian blue (PB) or an analogue thereof (PBA). The producing method comprises: (a) mixing a nanocube of PB or PBA with an acid solution to form a mixture; and (b) heating the mixture of the step (a) in an oil bath at 80-100° C. for 0.5 hours-1 month to produce the nanoframe of PB or PBA. Also encompassed herein is a method for treating a cancer in a subject in need thereof, which comprises administering an effective amount of a nanocube or a nanoframe of PB or PBA to the subject.

Abstract: The present invention relates to increasing and/or maintaining nitrogen content in soil by administration of nitrogen sources particles coated with urease inhibitors. In one embodiment, urease inhibitors are dispersed in an improved organo liquid delivery system at concentration levels of 60-95%. In another embodiment, urease inhibitors were applied in a non-aqueous, organo liquid delivery system coating nitrogen sources particles utilizing simple blending equipment at temperatures of 20°-70° C. Another embodiment discloses dry, flowable nitrogen sources coated with a urease inhibitor which can be administered directly to the soil, to a dry natural and/or a manmade fertilizer or to a liquid fertilizer which provides for the reduction of nitrogen loss from the soil. In another embodiment, a composition of urea and <0.2% dimethyl sulfoxide improves the crush resistance of the urea particles.

Abstract: Products of manufacture for delivering hydrogen, hydrogen peroxide, and/or oxygen to a tissue in need thereof comprising i) a hydrated hydrogel, and ii) at least one cathode electrode and at least one anode electrode implanted within or upon the hydrated hydrogel.

Abstract: Provided herein are containerized liquid formulations comprising a plurality of agrochemicals. The formulations comprise a plurality of parallel liquid layers, wherein each layer is disposed within the container such that it is in contact with at least one adjacent layer at an interface. Also provided are methods of preparing, storing, shipping, and using the containerized liquid formulations.

Abstract: Oral liquid formulations are provided containing sodium picosulfate, magnesium citrate, citric acid, malic acid, and an antioxidant selected from potassium metabisulfite and sodium metabisulfite, wherein the antioxidant is present in the composition at a concentration of from about 0.002 M to about 0.1 M, and wherein the composition has a pH of from about 4.0 to about 6.5.

Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Abstract: Disclosed herein is a method for preparing a softgel capsule including treating a softgel capsule with a solution including calcium salt, wherein the softgel capsule includes a fill material and a shell composition including pectin.

Abstract: Disclosed is a method for increasing the bud opening and/or longevity of cut flowers by exposing the cut flowers to an oxytocin solution and/or a variant and/or derivative thereof.

Abstract: A composition that prevents or slows the appearance of blemishes associated with inflammation of the skin and/or scalp, includes per 100% by mass: a) 60.0%-75.0% by mass of an organic solvent chosen from 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 1,3-butanediol, 1,2-butanediol, 2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,8-octanediol, or a blend of the above compounds; b) 0.1%-2.0% by mass of a composition including a mass quantity x1, expressed as mass equivalent of 1-O-(2-caffeyol)maloyl-3,5-O-dicaffeoylquinic acid, greater than or equal to 200 mg/g of a compound of general formula (I): in which Q1 and Q3-Q5 independently of each other represent the hydroxyl radical or a salt thereof or a radical selected among the caffeoyl, maloyl, caffeoyl maloyl and maloyl caffeoyl radicals; at least one of Q1 and Q3-Q5 represents neither the —OH radical nor a salt thereof; and c) 20.0%-35.0% by mass water.

Abstract: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, composite particles comprising a substrate formed from mica and from bismuth oxychloride coated with at least one mineral pigment and at least one nacre, chosen from composite particles comprising at least one support chosen from mica, synthetic fluorphlogopite or calcium sodium borosilicate, and completely or partially coated with one or more layers of metal oxides, in particular chosen from titanium dioxide, iron oxide, tin oxide and mixtures thereof. It also relates to the process for giving skin, and in particular facial skin, a uniform complexion and a rosy tonality, while at the same time retaining the natural appearance of the skin, which consists in applying at least one coat of a composition as defined above to the surface of the targeted skin.

Abstract: The disclosure relates generally to gamma polyglutamated aminopterin compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated aminopterin, and methods of making and using the gamma polyglutamated aminopterin compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

Abstract: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

Abstract: The present disclosure pertains to therapeutic hydrogels that comprise an anionic polysaccharide crosslinked by a branched polyamine, wherein the branched polyamine comprises at least two primary amine groups, more typically at least three primary amine groups. The present disclosure also pertains to medical compositions that comprise such therapeutic hydrogels and to methods of medical treatment in which such therapeutic hydrogels are delivered to a patient in need of medical treatment.